A number of studies have linked exposures to industrial and household chemicals and biological toxins to increased risk of autoimmunity in general and elevated levels of autoantibodies to neural antigens specifically. Elevated neural autoantibodies are biomarkers for many diseases such as multiple sclerosis and Parkinson's disease. Our study reports levels of six types of neural autoantibodies in a group of 24 toxicant-exposed patients. The patients were exposed to a variety of toxicants including contaminated drinking water (four patients), building water/mold damage (eight patients), pesticides (four patients), and other assorted toxic chemicals (eight patients). Levels of all six neural autoantibodies were significantly elevated in most patients and in the patient group at large, with mean antibody levels for the 24 chemically exposed patients (relative to a healthy control population), in descending order: 475% for tau proteins, 391% for microtubule associated proteins-2, 334% for neurofilament proteins (NFP), 302% for myelin basic protein, 299% for glial fibrillary acidic proteins, and 225% for tubulin. Tau protein autoantibodies were significantly elevated in the patient groups with peripheral neuropathy, muscle and joint pain, asthma, and chemical sensitivity. Autoantibodies to tubulin were significantly higher in the chemical sensitivity and asthma patients, autoantibodies to NFP were significantly higher in the patients with sleep apnea, whereas S-100B autoantibodies were significantly increased in patients with muscle/joint pain, asthma, and apnea/insomnia. In patients exposed to environmental toxicants, measurements of autoantibodies may be useful for prevention, diagnosis, and treatment. This study adds to the scientific literature the ability of a broad spectrum of environmental triggers adversely affecting the nervous system through the process of autoimmunity, which may explain the increasing incidence of neurodegenerative diseases.
Introduction
Humans are commonly exposed to many neurotoxic chemicals in the workplace and general environment, and many of these neurotoxicants can significantly increase the risk of many neurological and neuropsychiatric diseases and disorders. Toxic exposures have been implicated in the development and increased risk of neurodevelopmental and neurodegenerative diseases such as autism, attention deficit disorder, cognitive/motor deficits, peripheral neuropathy, multiple sclerosis, Alzheimer's disease, and Parkinson's disease (Bellinger, 2008; Baldi et al., 2001; Campbell et al., 2003; Chen et al., 2016; Chin-Chan et al., 2015; Crinnion, 2000; Curtis and Patel, 2008; Dick, 2006; Munoz-Quezada et al., 2013; Parron et al., 2011) . The recent review by Bondy outlines the neurodegenerative effects of many chemicals and explains the increasing incidence of neurodegenerative diseases (Bondy, 2016) .
Chronic neurological and non-neurological diseases may be caused, at least in part, by autoimmune processes. Occupational and environmental exposures, such as smoking, pesticides, organic solvents, silica, particulates, and heavy metals like lead and mercury, have been linked to a wide range of autoimmune diseases like rheumatoid arthritis, lupus, type 1 diabetes, Sjogren's disease, and autoimmune thyroid disease (Barragan-Martinez et al., 2012; Bodin et al., 2015; Duntas, 2011; Maciejewska, 2014; Wang et al., 2015) . Exposure to toxic chemicals can increase the risk of autoimmunity by many mechanisms including molecular mimicry, epitope spreading, apoptosis and other forms of cell death, and altered gene expression (Wang et al., 2015) . Exposure to many types of bacterial and viral infections, nutritional deficiencies (such as low vitamin D), and food allergens (such as gluten allergy) can also increase the risk of autoimmune disease (Bogdanos et al., 2015; Wang et al., 2015) .
Increased levels of autoantibodies to neural proteins have been seen in a number of inflammatory diseases of the central nervous system (CNS) and peripheral nervous system (PNS) including multiple sclerosis (Lalive, 2008; Schirmer et al., 2014) and chronic inflammatory demyelinating polyneuropathy (Nobile-Orazio and Giannotta, 2011; Steck et al., 2013) . Autoimmunity (and autoantibodies) may also play a major role in Alzheimer's and Parkinson's disease (Neff et al., 2008) .
Increased levels of autoantibodies to neural proteins have been seen in a number of populations exposed to toxic agents such as molds and mycotoxins (Campbell et al., 2003; Gray et al., 2003) , airplane flight crews exposed to hydraulic fluids (Abou-Donia et al., 2013a), solvent-contaminated domestic water supplies (Byers et al., 1988) , pesticides (Thrasher et al., 1993; El Rahman et al. 2017) , arsenic (AbouDonia et al., 2013b) gold miners exposed to mercury and other heavy metals (Gardner et al., 2010) , polychlorinated biphenyls, and perfluorinated compounds in children consuming a high fish diet (Osuna et al., 2014) . A recent study reported that neural autoantibodies were significantly higher (except for S-100B) in a group of 20 veterans with Gulf War syndrome patients (mean age 46 years) as compared to 10 controls with low back pain (mean age 50 years) (Abou-Donia et al., 2017) . The fold levels of neural autoantibodies in the Gulf War syndrome patients relative to controls were calcium-calmodulin kinase 9.27, glial fibrillary acidic protein (GFAP) 6.60, tau protein 4.83, tubulin 4.41, myelin associated glycoprotein (MAG) 3.60, myelin basic protein (MBP) 2.50, neurofilament protein (NFP) 2.45, microtubule associated protein-2 (MAP-2) 2.30, and S-100B protein 1.03 (Abou-Donia et al., 2017) .
Neural filaments are a major component of the neural cytoskeleton and are involved in axonal transport and neuronal function (Tagliaferro et al., 2006) . MAPs-2 play a role in promoting stabilization and polymerization of microtubules in axons and cross bridge neurofilaments (Hoshi et al., 1988) . Tau proteins are cytoskeletal proteins located mostly in the axons (Shiiya et al., 2004) . MBPs are membrane proteolipids produced by oligodendroglia in the CNS and by Schwan cells in the PNS (Jauch et al., 2006) . GFAPs are released by the astrocytes after CNS injury and cellular degeneration (Kovesdi et al., 2010) . Microtubules are composed of -and -tubulin forms, which constitute about 10% of total brain and are involved in axonal transport (Damodaran et al., 2011; Damodaran et al., 2009; Laferriere et al., 1997) .
The present study describes a group of 24 patients from an occupational and environmental medicine practice who were evaluated for six different neural autoantibodies including neurofilament proteins (NFP), MAPs-2, tau proteins, MBP, GFAPs, and tubulin. The S-100 protein (a marker for brain injury) was used as a control. The six proteins for which autoantibodies were measured in this study, all play different roles in the nervous system (Abou-Donia et al., 2013b) .
Materials and methods

Demographic data for subjects and controls
The 24 subjects, 6 males and 18 females, came from a clinical population seen by one of the authors (AL) over a 10-year period. The subjects' age ranged from 13 to 80 (mean + standard deviation (SD) 47.5 + 27.3) compared to 50 + 11 years for controls; all study participants were white (Table 1) . A detailed history was taken for each subject's occupational and environmental exposures, and the largest exposures was estimated by the authors. However, because of the retrospective nature of this study, measurements of the concentrations of toxins and toxicants in air, water and surfaces of the subject's occupational and environmental environments were not available for most subjects. Under a protocol approved by the Institutional Review Board at Duke University Medical Center, sera were collected from 12 healthy controls consisting of both genders and ranging from 31 to 63 years of age. The controls did not report any neurological symptoms.
Chemicals and other materials
Autoantibody tests were ordered for the subjects, and the data were analyzed at Duke University Medical Center in the laboratory of one of the authors (MBA).
The sources of proteins were neurofilament protein NFP, neurofilament protein low molecular weight NFL (70 kDa), neurofilament moderate molecular weight NFM (160kDa), neurofilament high molecular weight NFH (200 kDa, bovine spinal cord), tau protein (45-68 kDa, human), MAP-2 (300 kDa, bovine serum), tubulin (55 kDa, bovine brain), and MBP (33 kDa, human brain) from Sigma-Aldrich (Saint Louis, Missouri, USA); GFAP (52 kDa, human) from Biotrend Chemikalien GmbH (Cologne, Germany); and S-100B (9-14 kDa, human brain) from American Qualex International (San Clemente, California, USA). Horseradish peroxidase-conjugated goat antihuman IgG and enhanced chemiluminescence reagent were obtained from Amersham Pharmacia Biotech (Piscataway, New Jersey, USA). Sodium dodecyl sulfate (SDS) gels, 2-20% gradient (8 Â 8), and trisglycine at 15 mM were obtained from Invitrogen (Carlsbad, California, USA). All other materials were purchased from Amersham.
Western blot assay
To screen for the presence of autoantibodies against the battery of proteins, the proteins were separated using western blot assay. Each serum sample was a One of the pesticide-exposed patients also exposed to many mercury fillings and environment exposures during the first Persian Gulf War (1990 War ( -1991 . b One patient exposed to hairdresser chemicals also had saline breast implants. analyzed in triplicate. All proteins were loaded at 10 ng/lane except for albumin, which was loaded in a 100 ng/lane. Proteins were denatured and electrophoresed in SDS-polyacrylamide gel electrophoresis (4% to 20% gradient) purchased from Invitrogen. One gel was used for each serum sample. The proteins were transferred into polyvinylidene fluoride membranes (Amersham). Nonspecific binding sites were blocked with tris-buffered saline-Tween (TBST) (40 mM Tris (pH 7.6), 300 mM NaCl, and 0.1% Tween 20) containing 5% nonfat dry milk for 1 h at 22 C. Membranes were incubated with serum samples at 1:100 dilutions in TBST with 3% nonfat dry milk overnight at 4 C. After five washes in TBST, the membranes were incubated in a 1:2000 dilution of horseradish peroxidase-conjugated goat anti-human IgG (Amersham). The membranes were developed by enhanced chemiluminescence using the manufacturer's (Amersham) protocol and a Typhoon 8600 variable mode imager (General Electric Amersham Instruments, Buckinghamshire, UK). The signal intensity was quantified using PD Quest Bio-Rad image analysis software (Hercules, CA). All tests were performed with the investigators masked to diagnosis.
Specificity of sera autoantibodies
To check the specificity of the sera autoantibody, a peptide/antigen competition assay was performed and previously reported (Abou-Donia et al., 2013b) . In this assay, sera were mixed with the target protein or peptide with the objective of eliminating the binding of the autoantibody to the protein in the serum. Briefly, 50 ml of serum from three random subjects was mixed with or without 2 mg of tau, MAP or MBP in 100 ml phosphate-buffered saline and rotated overnight at 4 C. The serum/protein mix was centrifuged at 12,000 Â g to pellet any immune complexes. The supernatant was then removed and used for western blotting.
Calculations and statistics
Optical density measurement for subjects and healthy controls was divided by serum albumin density concentration; this value for each subject was normalized to controls and expressed as fold change from healthy controls. Thus, the results are expressed as mean values of triplicate assays of optical density arbitrary units normalized to albumin optical density as fold of healthy controls. The differences between mean neuro antibody levels were calculated for people with various adverse effects and a two-tailed t-test with unequal variances was employed to test for possible statistically significant differences.
Results
To detect autoantibodies in serum samples, we probed western blotting in individual serum samples. A total of 24 human serum samples underwent measurement of the levels of sera circulating IgG class autoantibodies against six neuronal-and glial-specific proteins. Table 1 lists patient demographics information. Six males and 18 females with ages ranging from 13 to 80 years old and mean of 47.5 were studied. Table 2 reports the environmental agents that the patients were exposed to. It shows that four subjects were exposed to contaminated water with the neurotoxicant/carcinogen, acrylamide, and hydrogen sulfide. Eight subjects were exposed indoors to mold, mycotoxins, and water damage. Four subjects were exposed to one or more pesticides including organophosphates, carbamates, pyrethroids, and organochlorines. Eight subjects were exposed to variety of chemicals including solvents, carbonless paper, freon, bleach, formaldehyde, paints, glues, hairdresser chemicals, and hydraulic fluid. None of the patients had a history of stroke, traumatic brain injury, and Parkinson's or Alzheimer's disease. The type of major health problems experienced are shown including chronic fatigue syndrome, fibromyalgia, depression, anxiety, headache, muscle and joint pain, and peripheral neuropathy are listed in Table 3 . The most common symptoms in the 24 subjects were neurological or largely neurological in nature including loss of cognitive function (18 subjects), chronic fatigue (14 subjects), depression/anxiety (11 subjects), and chronic headaches (11 subjects). Table 4 reports overall levels of neural autoantibodies in the 24 patients, along with data stratified by gender and age. The patients had autoantibodies several folds greater than that of the controls. The mean concentration of neural autoantibodies (with 100% being mean for control subjects) ranged from in descending order are tau 475 + 140, MAP-2 391 + 69, NFP 334 + 54, GFAP 299 + 44, MBP 302 + 32, tubulin 225 + 25, and S-100B 56 + 9. Each of the values for the seven autoantibodies was significantly higher (p < 0.001) for the exposed patients relative to controls with the exception of the S-100B values (Table 1, Figure 1 ). This table that also reports antibody data grouped by patient gender and age showing that the 18 female patients exhibited significantly increased autoantibodies against tau and MAP-2 as well as S-100B proteins. Table 5 reports data stratified by environmental exposure categories. Table 6 lists neural antibody levels stratified by the adverse health effects experienced. Mean neurofilament protein antibodies were significantly higher in sleep apnea/insomnia patients. Tau protein antibodies were significantly higher in the chemical sensitivity and peripheral neuropathy patients, whereas they were lower in muscle/joint and asthma patients. Tubulin protein antibodies were significantly higher in the chemical sensitive patients. The S-100B antibodies were significantly higher in the cognitive problem patients, chemical sensitivity patients, and asthma patients, while they were significantly lower in the apnea and insomnia patients.
Discussion
This study reports an elevated levels of autoantibodies to six neural proteins in a group of 24 patients with a wide variety of chemical/mold exposures and adverse health effects. Neural antibody levels were especially No significant differences were noted between groups at p ¼ 0. Table 6 . Neural autoantibody levels stratified by health effects. elevated in several patients. Several patients had autoantibody levels exceeding 1000% of an average healthy population for the MAP-2 and tau proteins. These included a 20-year-old man heavily exposed to the pesticide chlorpyrifos who had MAP-2 antibody levels 1203% of control average and tau antibody levels 1744% of control average and a 50-year-old woman exposed to a variety of chemicals in a poorly ventilated building near a paper mill who had MAP-2 antibody levels 1010% of control average and tau antibody levels 2870% of healthy controls. A number of studies have suggested that exposure to organophosphorus pesticides can damage neural and neuroskeletal proteins in a variety of ways including promoting hyperphosphorylation and other modifications of tau, tubulin, and MAP-2 proteins and abnormal microtubule formation (Abou-Donia et al., 2017a; Choudhary et al., 2001; Flaskos, 2014; Abou-Donia, 1994, 1999; Jiang et al., 2010; Patton et al., 1985; Suwita et al., 1986; Torres-Altoro et al., 2011) . Exposure to silicone breast implants has been associated with statistically significant increases in many types of autoantibodies levels in many studies and incidence of connective tissue diseases such as systemic sclerosis in some studies (Hajdu et al., 2011) . The effect of saline breast implants on autoimmunity is not clear. The 40-year-old woman in our study with exposure to saline breast implants and hairdresser work chemicals had autoantibody levels (relative to healthy controls) of 399% for NFP, 296% for MAP-2, 257% for tau, 474% for MBP, 770% for GFAP, and 257% for tubulin. Her 770% GFAP autoantibody value was the highest for the entire group of 24 patients.
Autoantibody levels to neural proteins may be useful biomarkers of effect for neurological disease and exposure to chemicals. It is possible that the elevated neural autoantibodies seen in this study were due to the chemical/mold exposures, related to the adverse health effects, or a combination of these two factors. Significantly elevated levels of autoantibodies to both neurofilament and GFAP have been seen in multiple sclerosis patients as compared to healthy controls, and higher levels of both neurofilament and GFAP autoantibodies have been associated with worsened disease severity and progression (Housley et al., 2015) . Significantly greater disability in patients with peripheral neuropathy associated with IgM monoclonal gammopathy (MGUS) was reported in patients with significantly higher levels of anti-myelin glycoproteins (Galassi et al., 2016) .
Limitations and future directions
This preliminary study has some limitations. The fairly small number of patients (24) and controls (12) gives the study limited statistical power when comparing to autoantibody levels related to age, gender, exposure, or type of adverse health effect. In addition, the exact concentrations of toxic chemicals and biotoxins were not available for most of the patients in this retrospective case series study. The retrospective "case series" nature of this study also has limitations in terms of the difficulty in collecting medical and environmental data for each control and patient in an identical manner. Further research on occupational and environmental exposures and neural autoantibodies should include well-funded prospective studies in which the levels of toxic exposures are carefully measured.
The current results show promise for further validation in a larger study sample. Future directions will be to compare these autoantibody markers with specific neurological outcomes including cognitive performance and brain imaging of gray and white matter volume and to further validate these suspected brainimmune neuropsychological outcomes. Greater basic understanding of the relationships between toxic exposure and autoimmunity may also be helpful in devising strategies to prevent and treat autoimmunerelated toxic injury. Neurological and neuropsychological long-term follow-up of these 24 patients would be of interest to see if they ultimately develop recognizable end-stage neurological disorders.
Conclusions
This study reported significantly elevated levels of six nervous system autoantibodies in a group of 24 patients exposed to various toxic agents. Exposures to a wide range of toxins can cause elevated levels of many neural autoantibodies. Increased levels of neural autoantibodies are associated with a wide range of adverse health effects including cognitive problems, chronic fatigue, depression, headaches, muscle/joint pain, peripheral neuropathy, and many others (see Table 2 ). With greater biotechnology, the use of gene arrays and other techniques may reveal the predisposing effect of genetics in many of the neurodegenerative diseases. This study adds to the axiom that genetics may load the gun, but it is the environment that pulls the trigger. It also supports the role of toxic chemicals in causing the increasing incidence of neurodegenerative diseases.
